Literature DB >> 2589356

Ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin.

K E Unertl1, F P Lenhart, H Forst, G Vogler, V Wilm, W Ehret, G Ruckdeschel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2589356     DOI: 10.1016/0002-9343(89)90041-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  8 in total

1.  High-Throughput Intracellular Antimicrobial Susceptibility Testing of Legionella pneumophila.

Authors:  Lucius Chiaraviglio; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

Review 2.  Systemic antibiotic treatment of nosocomial pneumonia.

Authors:  K E Unertl; F P Lenhart; H Forst; K Peter
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 3.  Optimum treatment of intracellular infection.

Authors:  M Maurin; D Raoult
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

4.  In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella.

Authors:  S J Martin; S L Pendland; C Chen; P Schreckenberger; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 5.  Treatment of Legionnaires' disease. Current recommendations.

Authors:  J Roig; A Carreres; C Domingo
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

6.  Nosocomial outbreak of legionellosis in a rehabilitation center. Demonstration of potable water as a source.

Authors:  R Nechwatal; W Ehret; O J Klatte; H J Zeissler; A Prull; H Lutz
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

Review 7.  Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors:  C Chidiac; Y Mouton
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 8.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.